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Multiple sclerosis (MS) is an autoimmune disease of the 
central nervous system (CNS) leading to demyelination, 
axonal damage, and progressive neurologic disability. 
The development of MS is influenced by environmental 
factors, particularly the Epstein-Barr virus (EBV), and 
genetic factors, which include specific HLA types, par-
ticularly DRB1*1501-DQA1*0102-DQB1*0602, and a 
predisposition to autoimmunity in general. MS patients 
have increased circulating T-cell and antibody reactivity 
to myelin proteins and gangliosides. It is proposed that 
the role of EBV is to infect autoreactive B cells that then 
seed the CNS and promote the survival of autoreactive  
T cells there. It is also proposed that the clinical attacks 
of relapsing-remitting MS are orchestrated by myelin-
reactive T cells entering the white matter of the CNS 
from the blood, and that the progressive disability in 
primary and secondary progressive MS is caused by 
the action of autoantibodies produced in the CNS by 
 meningeal lymphoid follicles with germinal centers.
Introduction
Multiple sclerosis (MS) is a chronic inflammatory demy­
elinating disease of the central nervous system (CNS) and 
a common cause of disability in young adults. Character­
istically, the disease affects the brain, spinal cord, and optic 
nerves in the CNS and spares the nerve roots and peripheral 
nerves in the peripheral nervous system. Typically the first 
symptoms of MS occur between the ages of 15 and 50 years, 
but they can commence as early as 3 years and as late as 
the seventh decade. Females are affected twice as often as 
males. Usually the disease has a relapsing­remitting course, 
with repeated neurologic episodes, each of which is followed 
by partial or complete recovery and a period free of new 
symptoms. Most patients with relapsing­remitting MS even­
tually develop secondary progressive MS, in which there is 
progressive deterioration independent of relapses. In about 
10% of patients, MS follows a primary progressive course, 
with a progressive neurologic deterioration from the onset, 
sometimes with superimposed relapses. Most patients live 
for at least 40 years after the onset of MS. The time course of 
neurologic disability in the different forms of MS is depicted 
at the bottom of Figure 1.
Based on a detailed analysis of the natural history of 
MS, Confavreux and Vukusic [1] recently proposed a unify­
ing concept to explain the different clinical courses of MS. 
They observed that the times to reach disability milestones, 
and the ages at which these landmarks are reached, follow 
a predefined schedule not obviously influenced by relapses, 
whenever they may occur, or by the initial course of the 
disease, whatever its type. They concluded that relapsing­
remitting MS can be regarded as MS in which insufficient 
time has elapsed for the conversion to secondary progressive 
MS; that secondary progressive MS is relapsing­remitting 
MS that has “grown older”; and that primary progressive 
MS is MS “amputated” from the usual preceding relapsing­ 
remitting phase.
There is now a large body of evidence indicating that 
MS is an autoimmune disease but, as with the other human 
chronic autoimmune diseases, the primary cause of this 
autoimmunity is unknown. An important line of evidence 
supporting a role for autoimmunity in the pathogenesis of 
MS derives from the ability to replicate the clinical and 
neuropathologic features of MS in experimental animals 
by immunization with proteins derived from CNS myelin. 
The induced disease initially was termed experimental 
allergic encephalomyelitis but is now labeled experimental 
autoimmune encephalomyelitis (EAE). More than 7000 
published articles on EAE have contributed to a large body 
of knowledge on mechanisms of immune­mediated dam­
age to the CNS in experimental animals, which guides 
much research in MS [2]. The key difference between EAE 
and MS is that the cause of the autoimmunity in EAE is 
known (immunization with myelin antigens or insertion of 
transgenes to generate encephalitogenic T lymphocytes), 
whereas the cause of the autoimmunity in MS is unknown. 
In this review, we discuss recent important advances in 
knowledge of the immune mechanisms contributing to the 
pathogenesis of MS.
Pathology in the CNS
In relapsing­remitting MS the typical lesions consist of 
focal inflammatory demyelinating lesions in the white 
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matter of the CNS [3]. The inflammatory infiltrate 
consists of T cells, B cells, macrophages, and activated 
microglia. The most characteristic feature of these lesions 
is primary demyelination, where there is removal of the 
myelin sheath around preserved axons; however, axonal 
transection also occurs in these areas of focal inflam­
matory demyelination. In contrast to relapsing­remitting 
MS, the neuropathology of secondary progressive MS and 
primary progressive MS is characterized by the presence 
of demyelination in the cerebral cortex and by less active 
inflammation in the focal white matter lesions [4•]. In 
progressive MS the cortical demyelination mainly affects 
the subpial layers of the cerebral cortex and is associated 
with mononuclear infiltration of the overlying meninges. 
Kutzelnigg et al. [4•] also found diffuse axonal injury in 
the cerebral white matter in primary progressive MS and 
secondary progressive MS, which they attributed to dif­
fuse mild inflammation in the white matter. An alternative 
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Figure 1. Proposed immunopathologic substrate of the different clinical courses of multiple sclerosis (MS). Coronal section of brain shows 
cerebral hemispheres, brainstem, and cerebellum, with graphs of time course of development of neurologic disability in relapsing-remitting 
MS (1), primary progressive MS (2), and secondary progressive MS (3). The immunopathology of relapsing-remitting MS is shown on the 
left half of the brain (1), and that of primary progressive MS is shown on the right half (2). Immunopathology of secondary progressive MS is 
initially that of relapsing-remitting MS (1), with later superimposition of immunopathology of primary progressive MS (2). It is proposed that 
in relapsing-remitting MS, the damage to central nervous system (CNS) white matter is mainly driven by autoreactive T cells entering the CNS 
from the blood, and that in primary progressive and secondary progressive MS it is driven by autoantibodies, which are produced by  
B cells in ectopic lymphoid follicles in the meninges and cause demyelination in adjacent underlying cerebral and cerebellar cortex. Men-
ingeal structures resembling lymphoid follicles with germinal centers have been found in secondary progressive MS but not yet in primary 
progressive MS [6••]. Demyelination is represented by white areas in the cerebral and cerebellar white matter and in the cerebral and 
cerebellar cortex. (Adapted from Diamond et al. [51]; with permission.)
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explanation for this diffuse axonal injury is axonal degen­
eration secondary to apoptosis of neurons and transection 
of axons in demyelinated cerebral cortex. Demyelination 
of the cortex of the cerebellum also occurs in primary 
progressive MS and secondary progressive MS, but not in 
relapsing­remitting MS [5].
An important recent observation is the finding of 
structures resembling B­cell lymphoid follicles with ger­
minal centers in the meninges of patients with secondary 
progressive MS [6••]. These ectopic lymphoid follicle­like 
structures contain B cells (some proliferating), plasma 
cells, T cells, and a network of follicular dendritic cells 
producing the chemokine CXCL13, which is chemotactic 
for B cells. These ectopic B­cell follicles are similar to 
those reported in the target organs of other human chronic 
autoimmune diseases, such as autoimmune thyroid dis­
ease [7]. In autoimmune thyroid disease the intrathyroidal 
germinal center B cells have been shown to be specific 
for thyroid autoantigens [7]. Thus it is possible that the 
germinal centers in the meninges of patients with MS are 
the sites of production, somatic hypermutation, and class­
switch recombination of B cells reactive against CNS 
antigens. Plasma cells differentiating from these meningeal 
B cells could produce antimyelin antibodies, which might 
induce demyelination in the adjacent underlying cerebral 
cortex and cerebellar cortex. They could also contribute 
to the synthesis of immunoglobulin (Ig) within the CNS, 
which is a diagnostic feature of MS [8]. Ectopic lymphoid 
follicles in the meninges could also be a site of activation 
and proliferation of CNS­reactive T cells. Serafini et al. 
[6••] did not find ectopic B­cell follicles in the meninges 
of either of two patients with primary progressive MS. 
However, given the occurrence of demyelination in the 
cerebral cortex and cerebellar cortex in primary progres­
sive MS as well as in secondary progressive MS [4•,5], it is 
possible that such follicles may also occur in the meninges 
of patients with primary progressive MS, although they 
may differ in size and distribution from those in second­
ary progressive MS. The proposed immunopathologic 
substrate underlying the different clinical courses of MS is 
diagrammatically illustrated in Figure 1.
HLA
MS is associated with HLA class II genes, specifically 
the HLA­DR2 or DRB1*15 haplotype (DRB1*1501­
DRB5*0101­DQA1*0102­DQB1*0602) in Caucasians, 
with approximately 65% of MS patients carrying this hap­
lotype, compared to approximately 30% of healthy controls 
[9]. A recent analysis of DRB1 variation in 1339 MS fami­
lies confirmed the strong association of MS with DRB1*15 
[10]. It also demonstrated a dominant DRB1*15 dose effect: 
DRB1*15/15 versus DRB1*X/X: odds ratio (OR) = 7.5, and 
DRB1*15/X versus DRB1*X/X: OR = 3.4. This study also 
revealed a modest recessive dose effect for DRB1*03, and 
a protective effect of DRB1*14. Furthermore, a significant 
DRB1*15 association was observed in primary progressive 
MS families, similar to relapsing­remitting MS families, 
suggesting that DRB1­restricted mechanisms are contribut­
ing to both phenotypes. Another recent study found that 
primary progressive MS is associated with HLA­DR alleles 
encoding HLA­DR molecules containing a glutamic acid 
residue at positions 71 or 74 of the HLA­DRβ1 chain [11]. 
Because the amino acids at these positions influence the 
shape and charge of pocket 4 of the antigen­binding groove 
of the HLA­DR molecule, these residues could influence 
the clinical course of MS by determining antigens targeted, 
with resultant protection from relapsing­remitting MS or 
susceptibility to primary progressive MS.
Association with Other Autoimmune Diseases
Patients with MS and their first­degree relatives have 
an increased risk of other autoimmune diseases, sug­
gesting that there is an underlying genetic susceptibility 
to autoimmunity in general [12,13]. Studies on auto­
immune family pedigrees have led to the proposal that 
autoimmunity in humans is an autosomal dominant 
trait with penetrance (disease expression) in about 92% 
of females and 49% of males carrying the abnormal 
gene, and with secondary genes, including HLA genes, 
determining the specific autoimmune disease [14]. A 
recent study of 176 families with two or more mem­
bers with MS revealed that other autoimmune diseases 
occurred in 26% of the index MS cases, and in one or 
more first­degree relatives in 64% of families [15•]. 
Hashimoto’s thyroiditis, psoriasis, and inflammatory 
bowel disease were the most common autoimmune dis­
eases in index cases and family members.
Autoreactivity to CNS Antigens in MS
Given the characteristic primary demyelination in the 
CNS in patients with MS and the experimental replica­
tion of this by immunization with myelin proteins, the 
most likely target autoantigens in MS are myelin antigens. 
Table 1 lists the proteins present in CNS myelin, together 
with their abundance and localization within the myelin 
sheath. Patients with MS have been shown to have T­cell 
reactivity to various myelin proteins, including myelin 
basic protein (MBP), myelin proteolipid protein (PLP), 
myelin/oligodendrocyte glycoprotein (MOG), oligoden­
drocyte­specific protein, myelin­associated glycoprotein, 
2', 3'­cyclic nucleotide 3' phosphodiesterase, and myelin­
associated oligodendrocytic basic protein [16]. However, 
the pathologic significance of this autoreactivity has 
been difficult to establish because T­cell reactivity to 
these myelin proteins is also found in healthy subjects. 
In one large study, increased circulating T­cell reactiv­
ity to amino acid residues 184­209 of PLP was found in 
patients with relapsing­remitting or secondary progres­
sive MS, compared with healthy subjects and patients 
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with other neurologic diseases [17]. PLP184­209 is a strong 
candidate autoantigen in MS because PLP is the most 
abundant CNS myelin protein (Table 1) and because 
PLP184­209 is encephalitogenic in mice, is immunodominant 
in humans, and is expressed on the extracellular surface 
of the myelin sheath, thereby also being a potential tar­
get for antibody­mediated demyelination. Longitudinal 
studies of T­cell reactivity to PLP184­209 in patients with 
MS have shown major fluctuations in the frequencies of 
these T cells in the blood, with surges partly correlating 
with MS disease activity [18].
Antibodies to myelin proteins may also have a patho­
genic role in MS because some patients have been shown 
to have antibody and complement deposition within 
active lesions [19,20]. Patients with MS have increased 
circulating anti­PLP antibodies, which can opsonize 
myelin for phagocytosis [21]. Recently, Zhou et al. [22] 
found that patients with MS, particularly those with pri­
mary progressive MS, have increased levels of serum IgG 
antibodies to native MOG. Zhou et al. [22] also observed 
that sera from patients with high anti­MOG antibody 
levels enhanced demyelination and axonal damage when 
transferred to animals with EAE. However, they did not 
attempt to block this pathogenic effect by adsorption with 
native MOG, and it therefore remains possible that the 
pathogenic effect of the sera was due to antibodies against 
other myelin components such as PLP.
In addition to myelin proteins, gangliosides are 
another potential source of target autoantigens in MS. 
Gangliosides are complex sialic acid–containing glyco­
sphingolipid components of the plasma membrane and 
are highly enriched in the CNS where they are expressed 
by neurons, astrocytes, and oligodendrocytes, the cells 
that form CNS myelin. Antibodies to gangliosides 
expressed in the peripheral nervous system are involved 
in the pathogenesis of many different forms of peripheral 
neuropathy. Patients with primary progressive MS have 
increased circulating T­cell and antibody reactivity to 
gangliosides, compared to healthy subjects and patients 
with other neurologic diseases [23,24]. Patients with sec­
ondary progressive MS also have increased circulating 
antiganglioside antibodies [23]. Recently Marconi et al. 
[25] reported that patients with MS, particularly those 
with secondary progressive MS, have increased serum 
IgM antibodies against the ganglioside GD2, which is 
expressed by oligodendrocytes.
Devic’s disease (neuromyelitis optica) is a variant of 
MS in which antibodies to a nonmyelin structure may have 
a pathogenic role. Neuromyelitis optica is characterized 
clinically by severe attacks of optic neuritis and myelitis 
and pathologically by inflammation, demyelination, and 
necrosis selectively involving the optic nerves and spinal 
cord. The inflammatory lesions consist of macrophages, 
granulocytes (particularly eosinophils), B cells, and a few 
T cells with a pronounced perivascular deposition of Ig 
(mainly IgM) and complement C9neo antigen (a marker 
of complement­mediated tissue injury) associated with 
prominent vascular fibrosis and hyalinization [26]. The 
extent of complement activation, eosinophilic infiltra­
tion, and vascular fibrosis in neuromyelitis optica is more 
prominent than in typical MS and suggests a pathogenic 
role for antibody directed at structures associated with 
Table 1. Proteins of CNS myelin
Protein Abundance Localization
Proteolipid protein (PLP)/DM20 ~50%–60% of CNS 
myelin protein
Integral membrane protein (tetraspanin) present 
throughout myelin lamellae, including on 
extracellular surface of myelin sheath
Myelin basic protein (MBP) ~30% of CNS myelin 
protein; also major 
component of PNS 
myelin
Intracellular—major dense line of myelin lamellae
Oligodendrocyte-specific protein (OSP) ~5%–10% of CNS 
myelin protein
Integral membrane protein
Myelin/oligodendrocyte glycoprotein (MOG)   0.05% of CNS myelin 
protein
Transmembrane Ig-like molecule present only 
on extracellular surface of myelin sheath
Myelin-associated oligodendrocytic basic 
protein (MOBP)
~5%–10% of CNS 
myelin protein
Intracellular—colocalized with MBP on major 
dense line
Myelin-associated glycoprotein (MAG) ~1% of CNS myelin 
protein; also present in 
PNS myelin (0.1% of 
PNS myelin protein)
Transmembrane adhesion molecule of Ig super-
family; glycoprotein with significant homology 
to N-CAM; restricted to periaxonal regions of 
myelin sheath
2',3'-cyclic nucleotide; 3' phosphodiesterase 
(CNPase)
< 1% of CNS myelin 
protein; also present in 
PNS myelin
Localized in cytoplasm of oligodendrocytes and 
Schwann cells; recognized by Rip antibody
CNS—central nervous system; Ig—immunoglobulin; N-CAM—neural cell adhesion molecule; PNS—peripheral nervous system.
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CNS blood vessels. Patients with neuromyelitis optica, but 
not patients with typical MS, have circulating IgG anti­
bodies that bind to the aquaporin­4 water channel, which 
is located in astrocytic foot processes on the abluminal 
face of microvessels in the CNS [27•].
Abnormalities in Cerebrospinal Fluid
A characteristic and diagnostic feature of the cerebrospinal 
fluid (CSF) in MS is the presence of oligoclonal bands of 
IgG, which are not present in the serum. This indicates 
IgG production in the CNS and is best detected by isoelec­
tric focusing on agarose gels followed by immunoblotting 
[8]. Oligoclonal bands of IgM restricted to the CSF can 
also be detected in some MS patients, and this correlates 
with more rapid clinical progression of neurologic dis­
ability [28]. A mononuclear CSF pleocytosis may also be 
present in patients with MS, particularly when the CSF is 
collected at the time of a clinical attack. The vast majority 
of the mononuclear cells in the CSF are T cells, with small 
proportions of B cells and monocytes [29]. Interestingly, 
a high ratio of CSF B cells to CSF monocytes correlates 
with an increased rate of progression of disability [29]. 
Analysis of the Ig heavy­chain variable region genes of 
B cells recovered from the CSF of MS patients has revealed 
a dominant monoclonal or dual­clonal B­cell expansion 
with evidence of somatic hypermutation, indicating that 
the B cells have passed through a germinal­center reaction 
[30]. This finding accords well with the recent demonstra­
tion of structures resembling lymphoid follicles containing 
germinal centers in the meninges of some patients with 
MS [6••], as discussed above.
Attempts to identify the antigen specificity of the 
oligoclonal Ig in the CSF have, until recently, been 
largely unsuccessful. To address this question, Cepok 
et al. [31•] screened CSF IgG with a protein expression 
array containing 37,000 tagged proteins generated from 
a human brain cDNA expression library. Interestingly, 
they found that the two most frequent MS­specific reac­
tivities were directed at peptide sequences derived from 
two proteins of the Epstein­Barr virus (EBV), namely 
Epstein­Barr nuclear antigen­1 (EBNA­1) and BRRF2. 
Cepok et al. [31•] found higher levels of IgG reactivity 
to EBNA­1 and BRRF2 in the serum and CSF of MS 
patients compared to patients with other neurologic 
diseases and showed that CSF oligoclonal IgG from MS 
patients specifically bound both EBV proteins. DNA 
has also been identified as a target of IgG produced in 
the CNS in MS [32]. Williamson et al. [32] found that 
antibodies binding specifically and with high affinity to 
double­stranded DNA were a significant component of 
IgG1 produced by B cells isolated from an active brain 
lesion of one MS patient and from the CSF of another 
MS patient. This finding is intriguing because of the 
occurrence of MS and systemic lupus erythematosus 
(SLE) in different members of the same family [12,15•] 
and because MS patients have an increased frequency 
of circulating antinuclear antibodies [33]. Recently, 
myelin lipids, particularly phosphatidylcholine, have 
been identified as antigens recognized by CSF oligo­
clonal IgM in MS patients [34]. In MS patients with 
oligoclonal IgM bands restricted to the CSF, the pre­
dominant B­cell population in the CSF comprises CD5+ 
B­1 B cells, a subset of B cells responsible for the secre­
tion of so­called natural antibodies, which are usually 
of IgM isotype and directed against nonprotein anti­
gens such as lipids [34].
Triggering of Attacks of MS  
by Systemic Infection
Attacks of MS are three times more likely to occur at 
the time of systemic infection (between 2 weeks before 
and 5 weeks after the onset of the first symptom of 
infection) than at other times [35]. In a recent study, 
Correale et al. [35] found that most of the attacks asso­
ciated with systemic infection occurred during the first 
2 weeks after the clinical onset of infection. They also 
found that viral and bacterial infections were equally 
associated with relapses of MS and that exacerbations 
associated with systemic infection were likely to be 
more severe and of longer duration than those not 
associated with infection. Possible mechanisms for the 
triggering of attacks by infections include a general 
upregulation of the immune system and cross­reactivity 
between microbial antigens and CNS antigens.
Role of EBV in Pathogenesis of MS
A large body of evidence indicates that infection with 
EBV has a role in the pathogenesis of many human 
chronic autoimmune diseases, including MS [36,37]. A 
review of eight published case­control studies compar­
ing EBV serology in MS patients and controls revealed 
that 99% of MS patients were EBV­seropositive 
compared to 90% of controls (OR = 13.5) [38]. This 
universally high seropositivity rate does not apply to 
other herpes viruses [39]. A recent study has shown 
that children with MS also have an EBV­seropositivity 
rate of 99%, compared to 72% in age­matched controls 
[40•]. This suggests that EBV infection is a causa sine 
qua non for the development of MS. Furthermore, a 
recent meta­analysis of 14 studies found that a clinical 
history of infectious mononucleosis, which indicates a 
late primary infection with EBV with a high frequency 
of infected B cells, increases the risk of MS, with a rela­
tive risk of 2.3 [41]. A study of blood samples collected 
from US military personnel before the onset of MS 
showed that the presence of high titers of IgG antibod­
ies to the EBNA complex increases the risk 36­fold for 
developing MS [42•]. This risk was associated with IgG 
antibodies to EBNA­1 but not EBNA­2.
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These studies suggest that, among infectious agents, 
EBV has a unique role in the pathogenesis of MS. The role 
of EBV is usually attributed to immunologic cross­reactivity 
between EBV antigens and CNS antigens. Because EBV has 
the unique ability to infect, activate, and latently persist in 
B lymphocytes, it has been suggested that the role of EBV 
in MS relates to EBV infection of autoreactive B cells [36]. 
EBV­infected CNS­reactive B cells might not only produce 
pathogenic autoantibodies but also lodge in the CNS, where 
they could act as professional antigen­presenting cells (APC) 
and present CNS antigens to activated CNS­reactive T cells 
trafficking through the CNS [36]. Healthy subjects experi­
ence surges of circulating CNS­reactive T cells, presumably 
activated by cross­reacting infectious agents [18]. It has been 
proposed that these T cells would normally be eliminated 
in the CNS by activation­induced apoptosis [43], as in ani­
mals with EAE [44–46], but could survive if they received 
costimulatory survival signals from professional APC in 
the CNS [43]. B cells infected by EBV might provide this 
costimulatory signal [36]. Infection of autoreactive B cells 
by EBV might also contribute to the pathogenesis of other 
autoimmune diseases [36,37], for example, SLE where 99% 
of patients are also EBV­seropositive [47]. 
Effect of Immunomodulatory Therapy
The importance of inflammation of the CNS in the 
pathogenesis of MS has recently been clearly demon­
strated by the beneficial clinical effect of natalizumab 
therapy in relapsing MS. Natalizumab blocks the entry 
of circulating lymphocytes and monocytes into the 
CNS by inhibiting the binding of leukocyte α4 integ­
rins to their receptors on vascular endothelial cells. 
In a large 2­year phase 3 trial, monthly intravenous 
infusions of natalizumab in patients with relapsing MS 
led to an 83% reduction in the accumulation of new 
or enlarging hyperintense lesions on T2­weighted mag­
netic resonance imaging of the brain, a 68% reduction 
in the rate of clinical relapse, and a 42% reduction in 
the risk of sustained progression of disability [48•]. 
However, because this therapy also blocks the normal 
immunosurveillance of the CNS by lymphocytes, it 
can be complicated by opportunistic infection of the 
CNS by the JC polyomavirus, which causes progres­
sive multifocal leukoencephalopathy, a usually fatal 
disease [49]. The importance of immune­mediated CNS 
damage in the pathogenesis of MS is also supported by 
the beneficial, albeit less dramatic, effects of therapy 
with other immunomodulatory agents such as high­
dose intravenous methylprednisolone, interferon­β, 
 glatiramer acetate, and mitoxantrone [50].
Proposed Scenario for Development of MS
We propose that the following scenario may lead to 
the development of MS. EBV infection in individu­
als genetically susceptible to autoimmunity results in a 
high frequency of EBV­infected memory B cells, pos­
sibly because of defective elimination of EBV­infected 
B cells by CD8+ T cells. The EBV­infected B cells include 
autoreactive memory B cells, which may seed the CNS. 
In those individuals with class II HLA types (such as 
DRB1*1501) which predispose to MS, common systemic 
infections lead to the activation of CD4+ T cells, which 
cross­react with CNS antigens and traffic into the CNS, 
where they are reactivated by EBV­infected B cells pre­
senting CNS antigens. These EBV­infected B cells provide 
costimulatory survival signals to the T cells and thereby 
inhibit the activation­induced T­cell apoptosis, which 
normally occurs when autoreactive T cells enter the CNS. 
The autoreactive T cells orchestrate an immune attack 
on the CNS through the recruitment of macrophages 
and B cells. CNS antigens released by this attack lead to 
spreading of the immune response to other CNS antigens. 
In most individuals the initial targets of the T cells are 
in the white matter of the CNS. This leads to a relaps­
ing­remitting course where clinical attacks are due to 
demyelination induced by autoreactive T cells entering the 
CNS from the blood and where remission is due to down­
regulation of the immune attack on the CNS followed 
by CNS remyelination by oligodendrocytes. Repeated 
T­cell attacks on the CNS supported by local EBV­infected 
B cells lead to the development, in the meninges, of struc­
tures resembling lymphoid follicles with germinal centers. 
These lymphoid follicles generate CNS­reactive B cells, 
which produce antibodies that diffuse into the adjacent 
underlying cerebral and cerebellar cortex and damage 
myelin and neurons there, leading to a secondary progres­
sive clinical course that is not dependent on the influx of 
autoreactive T cells from the blood. In a small proportion 
of individuals, the initial targets of the autoreactive T cells 
are in the gray matter of the CNS, resulting in clinically 
silent inflammation until the development of meningeal 
lymphoid follicles, which generate B cells producing 
antibodies that diffuse into the adjacent cerebral and cere­
bellar cortex and damage myelin and axons there, leading 
to a primary progressive clinical course (Fig. 1).
Conclusions
The development of MS is dependent on genetic fac­
tors, which include specific class II HLA types and a 
predisposition to autoimmunity in general, and envi­
ronmental factors, which include common infectious 
agents, particularly EBV. In relapsing­remitting MS, 
clinical attacks appear to be dependent on the entry of 
autoreactive T cells into the white matter of the CNS 
from the blood, whereas in primary and secondary pro­
gressive MS, the progressive disability might be caused 
by the action of autoantibodies produced in the CNS 
by B cells in meningeal structures resembling lymphoid 
follicles with germinal centers.
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